Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab Dan Turner, Anne M. Griffiths, Gigi Veerman, Jewel Johanns, Lakshmi Damaraju, Marion Blank, Jeffrey Hyams Clinical Gastroenterology and Hepatology Volume 11, Issue 11, Pages 1460-1465 (November 2013) DOI: 10.1016/j.cgh.2013.04.049 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Percentage of children in sustained steroid-free 1-year clinical remission, stratified by those achieving remission at week 8 by the PUCAI and MH. Clinical Gastroenterology and Hepatology 2013 11, 1460-1465DOI: (10.1016/j.cgh.2013.04.049) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Week 8 PUCAI score predicts 1-year steroid-free sustained remission. Clinical Gastroenterology and Hepatology 2013 11, 1460-1465DOI: (10.1016/j.cgh.2013.04.049) Copyright © 2013 AGA Institute Terms and Conditions
Figure 3 ROC curve to reflect the ability of the PUCAI, sigmoidoscopy, and CRP at week 8 to predict sustained steroid-free remission defined by PGA (A) or PaGA (B). AUC, area under the curve. Clinical Gastroenterology and Hepatology 2013 11, 1460-1465DOI: (10.1016/j.cgh.2013.04.049) Copyright © 2013 AGA Institute Terms and Conditions
Figure 4 Concordance between the PUCAI with sigmoidoscopic scoring (A) and with the Mayo scores (B) of 51 children 8 weeks after 3-dose induction with infliximab. Clinical Gastroenterology and Hepatology 2013 11, 1460-1465DOI: (10.1016/j.cgh.2013.04.049) Copyright © 2013 AGA Institute Terms and Conditions
Figure 5 The cutoff values of the PUCAI that correspond best with remission (A) and response (B) defined by the Mayo score. AUROC, area under the ROC curve. Clinical Gastroenterology and Hepatology 2013 11, 1460-1465DOI: (10.1016/j.cgh.2013.04.049) Copyright © 2013 AGA Institute Terms and Conditions